Full-Time
Develops cortisol modulators for medical conditions
$140k - $155k/yr
Senior
Lafayette, LA, USA
Required to travel up to 100% of the time, including up to 40% overnight travel.
Corcept Therapeutics develops cortisol modulators to help regulate cortisol levels in the body, focusing on serious medical conditions like Cushing's syndrome, which is caused by excessive cortisol. Their main product, Korlym (mifepristone), is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome patients. Corcept distinguishes itself from competitors by investing heavily in research and development of proprietary molecules and by supporting medical education for healthcare professionals and patients. The company's goal is to lead in cortisol modulation and improve treatment options for those affected by cortisol imbalances.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Menlo Park, California
Founded
1998
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Flexible Work Hours
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ:CORT) concerning possible violations of federal securities laws.
Corcept Therapeutics (NASDAQ: CORT) has launched the MOMENTUM clinical trial to investigate the prevalence of endogenous hypercortisolism (Cushing's syndrome) in patients with resistant hypertension.
The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma stock So Far in 2025.
Corcept introduced Korlym(R), the first FDA-approved treatment for Cushing's syndrome, in February 2012.